Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
176
resultados
Última actualización
03/11/2025 [06:50:00]
Resultados 125 a 150 de 176
Resumen de: US2025325493A1
Embodiments of the present disclosure provide novel compositions and methods for making and using polymer-coated nanocapsules. In certain embodiments, compositions and methods are disclosed for embedding at least one agent in a liquid fatty acid composition to form an inner core of the polymer-coated nanocapsule and coating the at least one agent-containing liquid fatty acid composition inner core with polymer to form at least one coating layer of polymer that further includes at least one positively charged surfactant (e.g., cationic surfactant), forming polymer-coated nanocapsules. In certain embodiments, the at least one positively charged surfactant binds to at least one targeting agent for directed use of the polymer-coated nanocapsules.
Resumen de: US2025325491A1
The invention relates to nanoparticles particularly for nanoparticles suitable for the delivery of a nucleic acid to a cell. The nanoparticles comprise polyvalent molecules to stabilise the nucleic acid molecules in the nanoparticles. Particularly the polyvalent molecules have a dendrimer like structure. The invention further relates to manufacturing nanoparticles, and uses of such nanoparticles in the treatment of a disease.
Resumen de: US2025325513A1
The present invention relates to a cabazitaxel prodrug anti-tumor preparation, designs and synthesizes a small molecule cabazitaxel prodrug with branched fatty alcohol involving formulas (I), (II) and (III) and containing different fatty alcohol side chains and different linking chains, and prepares a self-assembled nanoparticle. Results showed that the self-assembled nanoparticle of the small molecule cabazitaxel prodrug with branched fatty alcohol can effectively improve the efficacy of cabazitaxel, reduce toxic and side effects. The length of branched fatty alcohol side chains, the structure of the fatty alcohol side chains, the elemental composition of the linking chains and the length of the linking chains significantly affect preparation properties, in vivo fate and anti-tumor activity of the cabazitaxel-branched fatty alcohol prodrug self-assembled nanoparticle, which exhibits higher anti-tumor activity and lower toxicity compared with the self-assembled nanoparticle of small molecule cabazitaxel prodrug with straight-chain fatty alcohol.
Resumen de: US2025325655A1
A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21:50 μg/ml to 300 μg/ml; (2) Poly I:C: 400 μg/mL to 3000 μg/mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.
Resumen de: US2025325699A1
The invention features polypeptides containing nuclear localization sequences that can be used to deliver polynucleotides to a cell. The polypeptides can be formulated with a polynucleotide and a lipid.
Resumen de: US2025325695A1
The present invention provides a method of a prophylaxis or a treatment of a pathological change of Bruch's membrane and/or an adjacent tissue, including a retinal pigment epithelium, a choroid, and an optic nerve head of an eye, e.g. a calcification of Bruch's membrane and/or the adjacent tissue, using a nanoparticle comprising a scaffold comprising a biodegradable material, an antibody targeted to a component of a Bruch's membrane, a component of a sub-retinal pigment epithelial deposit, or a component of an optic nerve head, and an anti-calcifying agent. Additionally, the present invention provides a pharmaceutical composition comprising said nanoparticle and one or more pharmaceutical acceptable excipient(s). Said pharmaceutical composition could be used in a method of prophylaxis or treatment of a pathological change of Bruch's membrane and/or adjacent tissues, including a retinal pigment epithelium and a choroid of an eye and/or a calcified sub-retinal pigment epithelium deposit and/or a calcified drusen.
Resumen de: US2025325702A1
Compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation of misfolded transthyretin (TTR) proteins. Such conditions include, but are not limited to, polyneuropathy due to hereditary transthyretin amyloidosis (hATTR-PN) and hereditary cardiomyopathy due to transthyretin amyloidosis (hATTR-CM), both associated with autosomal dominant mutations of the TTR gene, and an age-related cardiomyopathy associated with wild-type TTR proteins (ATTRwt), also known as senile cardiac amyloidosis.
Resumen de: US2025325757A1
A cosmetic treatment method includes: applying, to skin or hair, an external preparation including a predetermined active ingredient and a base, and at least one of the active ingredient and the base contains fine water that is uncharged and has a particle size of less than or equal to 50 nanometers. Therefore, the applied fine water enters the skin or hair to contribute to maintenance of moisturization, and at the same time, forms a route through which the active ingredient permeates, thereby promoting the permeation of the active ingredient; therefore, the permeability of the active ingredient can be more appropriately improved.
Resumen de: US2025326708A1
The present disclosure relates to the field of medicine, specifically to a long-acting spleen-targeting cationic lipid compound comprising a benzene ring structure, a composition comprising the same, and a use thereof. More specifically, the present disclosure provides a compound of formula (I), or an N-oxide thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The present disclosure further provides a composition comprising the aforementioned compound and a use thereof in delivering therapeutic or prophylactic agents.
Resumen de: US2025326712A1
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by any of the formulae disclosed herein. The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations and pharmaceutical formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.
Resumen de: US2025326810A1
Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNFα) and a cytokine selected from the group consisting of Interferon gamma (IFNγ) and Interleukin-12.
Resumen de: WO2025217685A1
The present disclosure relates to quantum dot polymer compositions comprising a quantum dot, a polymer shell, optionally including a therapeutic agent and/or a target molecule, wherein the polymer shell comprises a first polymer layer comprising an endosomal disruptive polymer and a second polymer layer comprising a biopolymer suitable for oral administration. The present disclosure provides methods of making and using the compositions of the present disclosure.
Resumen de: WO2025217727A1
A conjugate compound comprises: TTA-X1-MNP-X2-TpA, wherein: TTA is a tumour targeting agent; MNP is a metal nanoparticle; TpA is a therapeutic agent; and X1 and X2 are the same or different, and are each independently selected from a non-covalent linker or a covalent linker. Methods for making the conjugate compound is provided. Methods and uses of the conjugate compound and a composition thereof for treating cancer.
Resumen de: WO2025217739A1
There is provided pharmaceutical compositions comprising disulfiram (DSF) or copper di-ethyldithiocarbamate (CuET), an indirubin compound such as 6-bromo-indirubin-3'-oxime (BIO), and a stabilizer, wherein the disulfiram or CuET, the indirubin compound, and the stabilizer are associated with a lipid nanoparticle. The pharmaceutical compositions are particularly suitable for treating a cancer overexpressing p97 and NPLOC4.
Resumen de: WO2025217985A1
Use of glucose-1-phosphate in the treatment of tumors. Specifically, provided are use of glucose-1-phosphate or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating tumors and use thereof in the preparation of a drug for enhancing tumor immunotherapy. In another aspect, provided is a nanoscale therapeutic agent, which comprises glucose-1-phosphate or a pharmaceutically acceptable salt thereof, a nanocarrier, and a reagent that specifically targets CD8+ T cells. The present invention relates to use of the nanoscale therapeutic agent in the preparation of a drug for treating tumors and use thereof in the preparation of a drug for enhancing tumor immunotherapy, and relates to a method for preparing the nanoscale therapeutic agent. Provided is a method for enhancing the anti-tumor activity of T cells in vitro.
Resumen de: WO2025218536A1
The present invention relates to lipid nanoparticles for targeted high-efficiency delivery of nucleic acid to the lung, an inhaled formulation comprising the lipid nanoparticles, and use of the lipid nanoparticles and the inhaled formulation in the preparation of a pharmaceutical composition for targeted delivery of the nucleic acid to the lung. The inhaled formulation of the lipid nanoparticles for targeted high-efficiency delivery of the nucleic acid to the lung can withstand shearing damage generated during atomization and overcome multiple physiological barriers to deliver the lipid nanoparticles to the lung, and it has high transfection efficiency.
Resumen de: WO2025219491A1
Provided are compositions and methods for transfecting a cell of hematopoietic lineage, using a lipid nanoparticle (LNP) that includes a lipid mix composition including an ionizable lipid, the lipid mix composition encapsulating an HDR template DNA comprising a gene of interest for insertion into a desired chromosomal locus.
Resumen de: WO2025219613A1
The present invention relates to particles comprising a polymer and DNA, wherein the DNA comprises at least one binding site capable of binding to RNA, in particular miRNA. Further, the invention is directed to a pharmaceutical composition comprising the particles and a pharmaceutically acceptable carrier. Moreover, the particles may be used in the treatment disease associated with RNA-overexpression.
Resumen de: WO2025219465A1
The invention relates to a hemoglobin-based oxygen carrier where the carrier has a metal-organic framework to entrap hemoglobin and is provided as nanoparticles; as well as a method for preparing the nanoparticles. The invention further relates to a pharmaceutical comprising the hemoglobin-based oxygen carrier.
Resumen de: WO2025221702A1
Provided is a nanoparticle including: a solid core comprising an active ingredient, a wax, and a carrier oil; a first shell surrounding the core, wherein the first shell comprises one or more proteins and one or more carbohydrates; and a second shell surrounding the first shell.
Resumen de: WO2025221757A1
The present invention relates to a carbohydrate-polymer conjugate comprising a repeat unit, a divalent linker, and a carbohydrate and compositions thereof, wherein the repeat unit comprises, in part, a linker and a carbohydrate, and a method comprising the step of administering a composition comprising the carbohydrate-polymer conjugate, wherein the composition can cross the blood-brain barrier.
Resumen de: WO2025221606A1
The present disclosure relates to compounds of the various formulas disclosed herein, including Formula (I) and Formula (II), and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising a compound of the various formulas disclosed herein, including Formula (I) and Formula (II), and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.
Resumen de: WO2025221397A1
The present disclosure provides a protein-based nanoparticle made of a protein and an amine for the delivery of a nucleic acid molecule, such as an mRNA vaccine, to a cell. The present disclosure further provides systems and methods for producing such protein-based nanoparticle including a nucleic acid molecule, and methods of delivering the nucleic acid molecule to a cell, and treating a subject with the compositions as disclosure herein.
Resumen de: AU2023392764A1
There is provided a pharmaceutical formulation that is useful in the treatment of metabolic disorders or conditions, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 µm; and (b) comprise solid cores comprising at least one glucagon-like peptide-1 receptor agonist, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is at least about 1:10 and up to and including about 10:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of glucagon-like peptide-1 receptor agonists to treat metabolic disorders or conditions, such as type 2 diabetes and/or obesity without a burst effect. The glucagon-like peptide-1 receptor agonist is preferably liraglutide.
Nº publicación: JP2025160197A 22/10/2025
Solicitante:
ユニバシダデデサンチャゴデコンポステラ
Resumen de: MX2021013091A
Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.
BOPI
Sede Electrónica
